Monographie - Epirubicin hydrochloride

Senaste uppdateringen :
08/05/2024

Epirubicin hydrochloride

Molekylstruktur

Varunamn

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Anthracine	Malaysia
Axirubicine	Tyskland
Bendaepi	Tyskland
Binarin	Mexiko
Bioepycina	Polen
Crisabon	Argentina
Cuatroepi	Argentina
Ecclepia	Rumänien
Elebicin	Mexiko
Ellence	Förenta Staterna
Epi Cell	Tyskland
Epidoxo	Argentina, Chile, Venezuela
Epifil	Ecuador
Epilem	Colombia, Mexiko
Epimedac	Tyskland
Epirubicin	Australien, Belgien, Danmark, Island, Nya Zeeland, Österrike, Saudi-Arabien, Schweiz, Storbritannien, Sverige, Turkiet, Ungern
Epirubicina	Argentina, Colombia, Ecuador, Mexiko, Rumänien, Spanien
Epirubicine	Belgien, Frankrike, Schweiz
Farmarubicin	Turkiet
Farmorubicin	Brasilien, Danmark, Finland, Grekland, Norge, Österrike, Saudi-Arabien, Schweiz, Sverige
Farmorubicin CSV	Sydafrikanska republiken
Farmorubicin PFS	Kroatien, Polen, Slovenien
Farmorubicin RD	Brasilien, Polen, Ryska, Schweiz
Farmorubicin RTU	Nederländerna
Farmorubicina	Brasilien, Italien, Portugal, Spanien
Farmorubicine	Belgien, Frankrike
Pharmorubicin	Storbritannien

Hänvisningar : Epirubicin hydrochloride

	Typ	Publikation
148	Tidningen	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525	Tidningen	De Vroe C, De Muynck C, Remon JP, Samsom M. A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters. Int J Pharm 1990 ; 65: 49-56.
683	Tidningen	Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C. Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 1990 ; 43: 265-272.
686	Tidningen	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
887	Tidningen	Pujol M, Munoz M, Prat J, Giona V, De Bolos J. Stability study of epirubicin in NaCl 0.9% injection. Ann Pharmacotherapy 1997 ; 31: 992-995.
1237	Tidningen	Keusters L, Stolk LML, Umans R, Van Asten P. Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation. Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265	Tidningen	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1317	Tidningen	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1662	Tidningen	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1823	Tidningen	Sewell GJ, Rigby-Jones AE, Priston MJ. Stability of intravesical epirubicin infusion: a sequential temperature study. J Clin Pharm Ther 2003 ; 28: 349-353.
1897	Tidningen	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1955	Tidningen	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
2168	Tidningen	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257	Laboratorium	Stability of epirubicin "Ebewe" infusion solutions. Ebewe Pharma 2007
3473	Tidningen	Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B. Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. Int J Pharm 2015 ; 495, 2: 956-962.
3474	Laboratorium	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3632	Laboratorium	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3670	Tidningen	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3708	Affisch	Sarakbi I, Thiesen J, Krämer I. Compatibility of epirubicin-loaded DC Beads with different contrast media. ECOP 2 Krakow 2014
3918	Tidningen	Sarakbi I, Krämer I. Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. J Oncol Pharm Practice 2016 ; 22: 749-756.
4352	Tidningen	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.

Mentions Légales